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Beijing/W genotype Mycobacterium tuberculosis is
widespread, may be increasing, and may have a predilec-
tion for drug resistance. Individual-level data on >29,000
patients from 49 studies in 35 countries were combined to
assess the Beijing genotype’s prevalence worldwide,
trends over time and with age, and associations with drug
resistance. We found 4 patterns for Beijing/W genotype
tuberculosis (TB): 1) endemic, not associated with drug
resistance (high level in most of East Asia, lower level in
parts of the United States); 2) epidemic, associated with
drug resistance (high level in Cuba, the former Soviet
Union, Vietnam, and South Africa, lower level in parts of
Western Europe); 3) epidemic but drug sensitive (Malawi,
Argentina); and 4) very low level or absent (parts of Europe,
Africa). This study confirms that Beijing/W genotype TB is
an emerging pathogen in several areas and a predominant
endemic strain in others; it is frequently associated with
drug resistance. 
The Mycobacterium tuberculosis genotype familyknown as “Beijing/W,” “W-Beijing,” or “Beijing” is
widespread (1–3). Described in 1995 as the prevalent
genotype in East Asia (4), >80% of strains from the
Beijing area were of this type. The multidrug-resistant W
strain is a member of the family. We use “Beijing” for the
whole genotype family. 
Researchers are concerned that the Beijing genotype
may have a predilection for developing drug resistance (5)
and may be spreading worldwide, perhaps as a result of
increased virulence (6). A systematic review of the pub-
lished literature in 2002 concluded that although Beijing
genotype tuberculosis (TB) was widespread, associations
with drug resistance varied, and little information on time
trends was available (2).
The review highlighted the problems of relying on
published literature: varying strain definitions; reporting
bias; and limited information on selection criteria, popu-
lation subgroups, age groups, or time trends. As part of the
European Concerted Action on New Generation Genetic
Markers and Techniques for the Epidemiology and
Control of Tuberculosis, we have combined available
datasets, using a common strain definition and individual-
level data.
Methods
Studies for inclusion were identified from the systemat-
ic review and from contacting members of the European
Concerted Action and authors of relevant articles pub-
lished since the review. We aimed to include as many stud-
ies as possible in which the proportion of TB caused by the
Beijing genotype could be ascertained in an unbiased way.
Studies could represent all or random samples of patients
in an area, hospital, or laboratory. Studies limited to out-
breaks, drug-resistant isolates, or of <30 patients were
excluded. A study description and individual patient data
that included at least the year the case was diagnosed and
the genotype were required. 
Strain Classification
Three methods identify Beijing genotype strains:
spoligotyping (7), IS6110 restriction fragment length poly-
morphism (RFLP) (8), and region A RFLP (9). The typical
Beijing spoligotype shows hybridization to spacers 35–43.
Beijing-like patterns with <9 spacers (but not solely spac-
ers 37–38, which represents M. microti), were included
(10). 
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By using IS6110 RFLP, fingerprints are compared to 19
patterns representative of the Beijing genotype (https://
hypocrates.rivm.nl/bnwww/index.html). With standard
techniques, allowing 1% position tolerance and classifying
all matches >80% as Beijing, these patterns have
96%–100% sensitivity and 98%–100% specificity to detect
Beijing strains, taking spoligotyping as the accepted stan-
dard (10). Sensitivity is increased by spoligotyping strains
with RFLP patterns that match 75%–80% to the reference
strains. The third technique uses a characteristic IS6110
insertion in region A. This method has 100% sensitivity and
98% specificity compared with spoligotyping (10). 
Analysis
The proportion of Beijing genotype strains in each
study was calculated overall and after excluding immi-
grants. The proportion of Beijing genotype in immigrants
was examined by place of birth. Time trends were exam-
ined directly and by examining trends with age; an associ-
ation with younger age groups would suggest that the
proportion of TB attributable to the Beijing genotype was
increasing. Associations with drug resistance were exam-
ined, after immigrants were excluded, with and without
excluding patients with previous TB. For pooled analyses,
heterogeneity in the associations between studies was
examined, and the results presented are adjusted for study. 
Results
Data were received from 49 studies representing 29,259
TB patients in 35 countries, including 11 studies from the
systematic review (2); other studies in the review had no
individual patient data available, used nonstandard case
definitions, or researchers declined to participate. Other
studies were contributed by members or contacts of the
Concerted Action or were identified from subsequently
published studies. Details of all included studies are shown
in online Appendix Table 1 (available from http://www.
cdc.gov/ncidod/EID/vol12no05/05-0400_app.htm). 
The proportion of tuberculosis due to the Beijing geno-
type in the included studies is shown in online Appendix
Table 2 (available from http://www.cdc.gov/ncidod/
EID/vol12no05/05-0400_app.htm#table2). 
Overall, 9.9% had the Beijing genotype. In Western
Europe and the Czech Republic, the proportion was low:
<6% of cases among nonimmigrants. In sub-Saharan
Africa, the proportion was low except in Cape Town,
South Africa. In Latin America, data were only available
from Argentina and Brazil; both studies found <1% of TB
cases were caused by Beijing genotype. In North America
and the Caribbean, the proportion was higher (8%–14%).
In the former Soviet Union the proportion was high:
45%–56% in Russia and 29% in Estonia. The proportion
was low in India (1%), higher in Bangladesh (7%), and
increased further east: >50% in many parts of Southeast
and East Asia.
Analyses by region of birth showed similar patterns
(Table 1). Beijing genotype strains were rare (0.5%)
among immigrants from Eastern Europe other than the for-
mer Soviet Union; most came from the former Yugoslavia.
The Beijing genotype was much less common among
immigrants from the Indian subcontinent (3.4%) than
among those from Southeast Asia (19%) or East Asia
(58%). Beijing genotype strains were uncommon among
immigrants from North Africa (3.0%), the Middle East
(5.2%), and sub-Saharan Africa (2.2%, including 50
[2.1%] of 2,427 persons from Somalia). Among Middle
Eastern immigrants, Beijing genotype was found in 6 (1%)
of 620 persons from Turkey but in 8 (9.9%) of 81 from
Afghanistan. 
Time Trends
Time trends were analyzed among nonimmigrants
within individual studies with >3 years of data (Table 2).
(Studies from France, Iran, Thailand, Vietnam, and Spain
are excluded because of small numbers in some years or
absence of Beijing genotype strains.) 
All Western European sites except London showed a
slight increase in Beijing strains over time, but this finding
was only significant in the Netherlands. Combining data
for Western Europe, the odds ratio (OR), adjusted for
study, for having the Beijing genotype in the later period
compared to the earlier period was 1.5 (95% confidence
interval [CI] 1.2–1.9). This figure was unchanged after
adjusting for age. The trend was similar after excluding the
Netherlands (adjusted OR 1.7, 95% CI 0.96–3.1). 
In St. Petersburg, Okayama, Buenos Aires, São Paulo,
and San Francisco, no significant change occurred over
time, but the studies only covered a few years. In Cape
Town and Malawi, significant increases occurred over
time and were unchanged after adjusting for age. 
Trends with Age
Trends with age for studies with >3 cases of Beijing
genotype TB among nonimmigrants are summarized in
Table 3. Most Western European studies found the highest
proportion of Beijing genotype TB in the youngest age
groups. Overall, for Western Europe, compared to those
age >50 years, the OR, adjusted for study,  of having the
Beijing genotype was 1.2 (0.87–1.6) for those 30–49 years
of age, and 2.4 (95% CI 1.8–3.3) for those <30 years of
age, ptrend<0.001. Excluding the Netherlands, the trend was
stronger: adjusted OR 2.2 (95% CI 1.1–4.2) for those
30–49 years of age and 3.9 (95% CI 1.9–7.9) for those <30
years of age, ptrend<0.001.
In Russia and Estonia, Beijing genotype strains were
more common in younger patients, and the trend was
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significant in St. Petersburg (p = 0.02). Overall, compared
to those >50 years of age, the study-adjusted OR was 1.1
(95% CI 0.70–1.8) for those 30–49 years of age and 1.7
(95% CI 1.1–2.9) for those <30 years of age, ptrend = 0.02.
The African studies that found any Beijing strains noted
a higher proportion in younger persons than in older per-
sons. This difference was not significant in individual stud-
ies but was when studies were combined: study-adjusted
OR, 1.9 (95% CI 1.1–3.4) for those 30–49 years of age and
2.1 (95% CI 1.2–3.7) for those <30 years of age, compared
to those >50 years of age, ptrend = 0.03.
Among nonimmigrants in US studies, no significant
trend occurred with age, either individually or overall. In
Cuba, Beijing genotypes were more common in younger
persons than in older persons in the larger study and over-
all (ptrend = 0.06). In Buenos Aires and São Paulo, all
Beijing genotype–infected patients were <30 years of age
(p = 0.002). 
Most Asian studies showed no association with age, but
trends were seen in Bangladesh, Vietnam, and Hong Kong.
In Vietnam, Beijing genotype was more common in
younger patients in all 4 studies: overall, compared to
those >50 years of age, the study-adjusted OR was 1.5
(95% CI 1.0–2.2) for those 30–49 years of age and 2.7
(95% CI 1.7–4.2) for those <30 years of age, ptrend<0.001.
In Hong Kong, Beijing genotypes were least common in
patients <30 years of age. 
Drug Resistance
Studies with drug resistance data for all or most patients
and with >3 Beijing genotype TB patients among nonim-
migrants are summarized in online Appendix Table 3
(available at http://www.cdc.gov/ncidod/EID/vol12no05/
05-0400_app.htm#table3). In the Western European stud-
ies, with the exception of inner London, resistance was
more common among Beijing genotype strains than
among other strains. Beijing genotype was significantly
associated with resistance in Denmark (rifampin and
ethambutol), Finland (rifampin and streptomycin), and the
Netherlands (streptomycin). Overall, the study-adjusted
OR for the association of Beijing genotype and resistance
among nonimmigrants in Western Europe was 1.8 (95% CI
1.2–2.7) for any drug, 1.7 (95% CI 0.95–2.9) for isoniazid,
4.0 (95% CI 1.4–11.9) for rifampin, 2.3 (95% CI 1.4–3.7)
for streptomycin, 3.0 (95% CI 0.38–23.2) for ethambutol,
and 4.2 (95% CI 1.2–14.7) for multidrug resistance (i.e.,
resistance to at least isoniazid and rifampin). Of the
Western European studies, only those from Denmark,
Hamburg, the Netherlands, and London had data on previ-
ous treatment. After patients who had previously received
treatment were excluded, the associations in the
Netherlands and Denmark persisted, and the adjusted com-
bined ORs were similar to those overall but with wider CIs
(e.g., 1.6, 95% CI 1.0–2.6 for any drug resistance).
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In Russia and Estonia, Beijing genotype was strongly
associated with resistance to all tested drugs. None of the
patients in Estonia had been previously treated. In the
Archangel Oblast, the association persisted after previous-
ly treated patients were excluded, but in St. Petersburg only
the association with isoniazid resistance remained signifi-
cant. In Cuba, Beijing genotype was associated with strep-
tomycin resistance in both studies, and this association
persisted after previously treated patients were excluded.
In Malawi and Zimbabwe, none of the Beijing geno-
type isolates was drug resistant. In Cape Town, 14 (35%)
of the 40 Beijing isolates that were tested were drug resist-
ant, but the resistance of most Beijing isolates and of the
other isolates was unknown. 
In the Asian studies, only those in Bangladesh,
Vietnam, and Taiwan found more drug resistance in
Beijing genotype strains. In Bangladesh, 99% of the
patients had previously received treatment for TB. In
Vietnam, the results were little changed by excluding the
few previously treated patients. In Taiwan, previous treat-
ment was unknown. Two studies found that Beijing geno-
types were less commonly drug resistant. In China, Beijing
genotypes were less likely to exhibit ethambutol resist-
ance; no information was available on previous treatment.
In Malaysia, among patients without previous treatment, 1
(2%) of 48 isolates from patients with the Beijing genotype
and 33 (13%) of 252 isolates from patients with other
genotypes were resistant to any drugs (p = 0.03).
Other Associations
In most studies, the proportion of nonimmigrants with
the Beijing genotype was similar for men and women. In
Japan, the proportion was higher among men, and in
Malawi, it was higher among women. Only 23 studies had
data on HIV status in nonimmigrants, and of these, 13
found no Beijing genotype, no HIV-positive patients, or
information was lacking on HIV status of the patients with
Beijing genotype. In the 10 remaining studies (inner
London, Lyon, the Netherlands, Tuscany, San Francisco,
Cuba [both studies], Buenos Aires, Malawi, and Ho Chi
Minh City), no association was found between HIV status
and Beijing genotype. 
No significant association was found between strain
type and site of tuberculosis (pulmonary or extrapul-
monary) in any of the 20 studies in which this information
was available and both types of tuberculosis were included.
In Cuba, outside Havana, and in the Archangel Oblast
patients with recurrent TB were more likely than patients in
their first episode of disease to have the Beijing genotype,
but these associations were lost after adjusting for drug
resistance. No associations with previous TB were found in
any of the other 17 studies for which information was avail-
able, but the numbers of recurrent cases were often small.
Discussion
In this study, we have brought together published and
unpublished data to document the spread of Beijing geno-
type tuberculosis worldwide. Little information was avail-
able from many countries including most of the Americas,
Eastern Europe, North Africa, the Middle East, and
Australasia. All eligible studies were requested, whether
Beijing genotypes were found or not, and within the
included studies, the proportion with Beijing genotype
should be representative of those settings. The individual-
level data allowed comparable analyses in all sites and
pooled analysis within regions. This study complements
the spoligotype database (3), which includes only studies
that used spoligotyping and is more inclusive and less
detailed epidemiologically. The database shows a similar
global distribution of the Beijing genotype to that
described here.
The proportion of TB attributable to the Beijing geno-
type is variable: high in Asia, apart from the Indian sub-
continent, increasing further east; low in parts of Africa,
Latin America, and Western Europe; intermediate in the
United States and Cuba; low in Eastern Europe (other than
the former Soviet Union); low in the Middle East (includ-
ing <1% in a recent study from Tehran [11]). In Western
Europe, Beijing genotype is more common among immi-
grant TB patients than among indigenous patients. The
proportion of Beijing genotype TB among nonimmigrants
may reflect the importance of immigrants to the total TB
prevalence in these countries as well as the origin of these
immigrants. Immigrants accounted for >50% of TB cases
in London, the Netherlands, France, Denmark, Sweden,
and Hamburg, compared to 25% of cases in Italy, 24% in
Austria, 8% in Finland, and 4% in Spain. 
Using information from time and age group trends, we
found that an increasing proportion of TB is due to Beijing
genotype strains in Western Europe, southern Africa, and
the former Soviet Union. We found little evidence of
increase in Asia, except in Vietnam and Bangladesh.
Strong associations with drug resistance have been
found in the former Soviet Union, Cuba, and Vietnam. The
combined data for Western Europe suggest an association
there. No association was found in a large study in Malawi
or in most of the Asian studies.
When the data on trends and drug resistance presented
here and from other studies are combined, the results sug-
gest that the distribution of Beijing genotype TB has sever-
al patterns (Figure). The Beijing genotype probably
originated in the Beijing region of China (1,4); it was found
in 90% of stored biopsy specimens in the 1950s, and this
proportion has not changed over time (12). Beijing strains
appear to have spread and become established as the pre-
dominant M. tuberculosis genotype in much of East and
Southeast Asia, so little evidence of increase was found. In
TUBERCULOSIS RESEARCH
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these areas, the Beijing genotype appears to be endemic and
not associated with drug resistance (pattern 1).
In certain areas, including the former Soviet Union (13),
Cuba, and Cape Town, epidemic spread was found, which
was associated with drug resistance (pattern 2). Vietnam
and Bangladesh follow this pattern, unlike most other Asian
countries. Recent Indian studies suggest that India may also
fit pattern 2 (14,15). In Taiwan, the association with drug
resistance was not confirmed in a larger sample in 2003
(unpub. data), which suggests that it follows pattern 1. In
parts of Western Europe, although the Beijing genotype
remains uncommon, it appears to be increasing and is asso-
ciated with drug resistance (pattern 2). 
In the United States, the pattern is mixed. Non-
immigrant patients in San Francisco fit pattern 1: no asso-
ciation with drug resistance and no evidence of time
trends. In this area, most Beijing isolates came from Asian
immigrants, among whom no association was found
between Beijing genotype and drug resistance. In the New
Jersey study, no data on drug resistance were available, but
a previous study in this area found that most Beijing iso-
lates from nonimmigrants were pansusceptible (1,16). The
age distribution does not suggest recent increase, which
fits pattern 1. In contrast, the spread of the multidrug-
resistant W strain in New York and beyond during the
1990s has been well documented (17–19). Other published
studies from the United States confirm that the Beijing
genotype is widespread but do not report drug resistance or
trends (20–23).
In Malawi, an increase in the Beijing genotype over
time was documented, but with drug sensitive strains (pat-
tern 3). Argentina may fit this pattern, and spread of drug-
sensitive Beijing genotype TB has been described in Gran
Canaria (24). The final pattern (pattern 4) is of very low
level or absent Beijing genotypes, as seen in parts of Africa
and Europe. 
The wide distribution of the Beijing genotype could be
attributable to a founder effect or random drift, though
these mechanisms would be unlikely to account for recent
increases in multiple settings. The distribution could
reflect particular stability of the genetic markers used to
identify the genotype. High levels and epidemic spread
may suggest that it transmits more easily or is more viru-
lent than other strains. In vitro and animal studies have
suggested increased multiplication or virulence for some
Beijing strains (6,25) but not others (26). In Vietnam, the
Beijing genotype was associated with treatment failure and
relapse (27), but we found no such association. In
Indonesia, patients with the Beijing genotype had a similar
clinical picture to other TB patients for almost all parame-
ters studied (28). In the Netherlands, the appearance on
chest radiograph was similar for patients infected with
Beijing genotype and for other TB patients (29). In
Malawi, the Beijing genotype was not associated with
death or transmissibility (30).
External factors may select for Beijing strains. In the
former Soviet Union and the United States, spread has
been associated with prisons and with high rates of drug
resistance (13,17,31,32). In Mongolia, data were also
available from prisoners. They had a higher proportion of
Beijing genotype than did other patients, 46 (82%) of 56
compared to 97 (58%) of 168, p = 0.001, and a higher
Beijing/W Genotype M. tuberculosis and Drug Resistance
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Figure. Distribution of Beijing
genotype tuberculosis (TB).
Size of circle indicates per-
centage of TB cases due to
Beijing genotype; color in cir-
cle indicates drug sensitivity
and distribution trend. Blue,
pattern 1 (stable, no associa-
tion with drug resistance); red,
pattern 2 (increasing, associ-
ated with drug resistance);
green, pattern 3 (increasing,
drug sensitive); yellow, pattern
4 (absent); striped, trend or
association with drug resist-
ance not known.
prevalence of drug resistance. Population movements (33),
for example, from the former Soviet Union into Western
Europe and through Afghanistan, may account for spread,
recent increases, and the association with drug resistance
(34).
Beijing genotypes may have a particular propensity to
acquire drug resistance. Mutations in putative mutator
genes have been found in Beijing genotypes, which sug-
gests adaptability (5), but no increase in the rate of acqui-
sition of resistance to rifampicin was found in in vitro
studies (35). Once established, resistance could encourage
spread if it delays effective treatment. Although the fitness
of resistant strains is slightly reduced, this may be less
marked for Beijing strains (36). 
Conclusion
This study has confirmed that Beijing genotype M.
tuberculosis is an emerging infection in many parts of the
world and is a highly endemic pathogen in other areas. Its
association with drug resistance, sometimes at high levels,
in a number of settings, underlines its importance. The rea-
sons for its apparent success are not well understood but
may depend on human population movements as well as
on any intrinsic factors.
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